Jafron Biomedical Co Ltd
SZSE:300529
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.6
37.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Jafron Biomedical Co Ltd
PP&E Net
Jafron Biomedical Co Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
PP&E Net
¥1.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
PP&E Net
¥464.5m
|
CAGR 3-Years
43%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
PP&E Net
¥2.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
17%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
PP&E Net
¥9.4B
|
CAGR 3-Years
23%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
PP&E Net
¥5.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
PP&E Net
¥3.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jafron Biomedical Co Ltd
Glance View
Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.
See Also
What is Jafron Biomedical Co Ltd's PP&E Net?
PP&E Net
1.9B
CNY
Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's PP&E Net amounts to 1.9B CNY.
What is Jafron Biomedical Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
24%
Over the last year, the PP&E Net growth was 3%. The average annual PP&E Net growth rates for Jafron Biomedical Co Ltd have been 16% over the past three years , 24% over the past five years .
You don't have any saved screeners yet
